Initiation, adherence to AIs low for older women with DCIS

(HealthDay)—For older women with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS), initiation of aromatase inhibitors (AIs) and adherence to treatment are low, according to a study published online Oct. 25 in Cancer.

Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial - ScienceDirect

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II - ScienceDirect

PDF) Does patient health literacy impact adherence to adjuvant endocrine therapy in breast cancer patients?

Breast Cancer in Older Women

Frontiers Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer

Factors associated with adherence to medications for lowering breast cancer risk between female Medicare beneficiaries in Alabama and nationwide

Cancers, Free Full-Text

Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer

Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study

PDF) Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: A systematic review

Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer - Data Points Publication Series - NCBI Bookshelf

Adjuvant Hormonal Therapy Adherence in Breast Cancer - BCTT

Breast Cancer